tiprankstipranks
Cue Biopharma initiated with a Buy at Jefferies
PremiumThe FlyCue Biopharma initiated with a Buy at Jefferies
1M ago
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
PremiumPress Releases
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
2M ago
Cue Biopharma presenting data on lead clinical asset CUE-101 at symposium
PremiumThe Fly
Cue Biopharma presenting data on lead clinical asset CUE-101 at symposium
2M ago
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023
PremiumPress ReleasesCue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023
6M ago
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
PremiumPress Releases
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
7M ago
Cue Biopharma completes patient enrollment in Phase 1b study of CUE-101
PremiumThe Fly
Cue Biopharma completes patient enrollment in Phase 1b study of CUE-101
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100